- RXI-109 is a self-delivering RNAi (sd-rxRNA®) compound that targets connective tissue growth factor (CTGF), a key regulator of fibrosis and scar formation.
- Study successfully meets primary objective by showing that RXI-109 is safe and well tolerated in this dose escalation study.
- RXI-109 meets secondary objectives with improved or stable disease in the study eyes.
PR Newswire
MARLBOROUGH, Mass., Aug. 1, 2018